IMBiologics아이엠바이오로직스
493280 · KOSDAQ · ₩493280 · 아이엠바이오로직스
- Market cap
- ₩205B
- Enterprise value
- ₩82B
- P/E
- 233.6×
- P/B
- 1.6×
- Dividend yield
- 0.0%
- ROE
- 0.7%
- Net margin
- 7.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−86.7% from the high
₩13,190Today: ₩13,630 – ₩14,590₩104,000
Returns
- 1W−3.6%
- 1M−20.1%
- 3M0.0%
- 6M−71.6%
- YTD−86.7%
- 1Y—
- Volume today
- 96,371
- 0.8× the 20-day average
- Traded today
- ₩1.3B
- Listed shares
- 14,845,961
- EPS (12 months)
- ₩59
- Earnings yield 0.4%
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumWeak-21.9% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
IMBiologics stock overview
IMBiologics (아이엠바이오로직스, KRX: 493280) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a biotech founded in August 2020 that develops innovative antibody drugs for autoimmune diseases and immuno-oncology using its proprietary antibody platform, IM-OpDECon, which designs and optimizes various antibody formats, including single, dual, and multi-target molecules. Its shares closed at ₩13,800 on Oct 29, 2026, down 3.02% on the day, giving it a market value of ₩205B.
Key facts
- Market cap
- ₩205B
- Sector
- Biotech & Pharma
- Latest price change
- −3.02%
- As of
- Oct 29, 2026
- Main business
- The company is a biotech founded in August 2020 that develops innovative antibody drugs for autoimmune diseases and immuno-oncology using its proprietary antibody platform, IM-OpDECon, which designs and optimizes various antibody formats, including single, dual, and multi-target molecules.
Quick answers about IMBiologics
- What does IMBiologics do?
- The company is a biotech founded in August 2020 that develops innovative antibody drugs for autoimmune diseases and immuno-oncology using its proprietary antibody platform, IM-OpDECon, which designs and optimizes various antibody formats, including single, dual, and multi-target molecules. Its lead pipeline candidates, IMB-101 (an OX40L/TNF bispecific antibody for hidradenitis suppurativa) and IMB-102 (an OX40L monoclonal antibody for atopic dermatitis), have been out-licensed to Navigator Medicines, with its revenue coming from technology transfer and services.
- What is the market cap of IMBiologics?
- The market capitalisation of IMBiologics was ₩205B at the close on Oct 29, 2026.
- Who are the largest shareholders of IMBiologics?
- According to the latest official filings, the largest reported holders are Ha Gyeong-sik (36.49%, as of Jun 12, 2026); ATINUM Investment (11.00%, as of Mar 27, 2026); Partners 9th Investment Partnership (6.06%, as of Mar 27, 2026).
- When is the next earnings report from IMBiologics?
- Korean companies rarely announce results dates in advance. Based on when IMBiologics filed the same report in past years, its next annual results is expected around Mar 25, 2027.
Company profile
The company is a biotech founded in August 2020 that develops innovative antibody drugs for autoimmune diseases and immuno-oncology using its proprietary antibody platform, IM-OpDECon, which designs and optimizes various antibody formats, including single, dual, and multi-target molecules. Its lead pipeline candidates, IMB-101 (an OX40L/TNF bispecific antibody for hidradenitis suppurativa) and IMB-102 (an OX40L monoclonal antibody for atopic dermatitis), have been out-licensed to Navigator Medicines, with its revenue coming from technology transfer and services.
Written by AI from the company's latest annual report.
- Korean name
- 아이엠바이오로직스
- Sector
- Biotech & Pharma
- CEO
- 하경식
- Founded
- Aug 2020
- Listed
- Mar 2026
- Listed shares
- 14,845,961
- Fiscal year ends
- Month 12
- Website
- imbiologics.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Investor relations (IR) eventOct 19, 2026
- 5%+ holding reportSep 10, 2026
- Investor relations (IR) eventSep 8, 2026
- Half-year report (Jun 2026)Aug 12, 2026
- 5%+ holding reportJun 12, 2026
Titles in Korean until English translations are added.
Also known as: IMBiologics / 아이엠바이오로직스 / 493280 / KRX:493280
Source: KRX statistical information